The management of hyperlipidemia in those without renal dysfunction is based on multiple factors, including age, low-density lipoprotein (LDL) cholesterol levels, the presence of diabetes mellitus, a history of cardiovascular disease (CVD), and the 10-year risk of atherosclerotic cardiovascular disease (ASCVD).1 However, primary and secondary prevention of CVD in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) differs from that of the general population. Multiple trials and meta-analyses have been done to determine how aggressively hyperlipidemia should be treated to reduce morbidity and mortality in this unique population. The following are points to remember when treating hyperlipidemia in patients with CKD and ESRD.